Mykofenolatmofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolatmofetil Accord, is an antimetabolite immunosuppressant presented as an intravenous solution for intravenous use. It is employed to prevent acute rejection and to maintain long‑term immunosuppression in kidney, heart, liver and other solid‑organ transplants. GNH USA supplies Mykofenolatmofetil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Mycophenolate Mofetil is used in the immunosuppressive pathway to prevent organ rejection.

Kidney transplantation: helps prevent acute rejection and supports long‑term graft survival. Heart transplantation: reduces the incidence of acute rejection episodes. Liver transplantation: maintains immunosuppression to protect graft function.

Adverse reactions may occur with Mycophenolate Mofetil therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Tremor: fine shaking of hands or limbs. - Leukopenia: reduced white blood cell count. - Anemia: lowered red blood cell levels.

Serious or Rare Side Effects: - Infections: opportunistic or severe bacterial, viral, or fungal infections. - Malignancy: increased risk of post‑transplant lymphoproliferative disorders. - Severe neutropenia: marked drop in neutrophils, raising infection risk. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease of the CNS.

Mykofenolatmofetil Accord requires careful monitoring and patient counseling.

Renal function: monitor serum creatinine and adjust therapy as needed. Hepatic function: assess liver enzymes regularly. Infection risk: screen for latent infections before initiation and monitor for new infections. Pregnancy: Category D; avoid use in pregnant women unless benefits outweigh risks. Vaccination: avoid live vaccines during treatment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mycophenolate Mofetil may interact with several agents that affect its safety or efficacy.

Major Interactions (Avoid): - Cyclosporine: increases mycophenolate exposure, requiring close monitoring. - Tacrolimus: may heighten nephrotoxicity risk. - Live vaccines: can cause severe infection in immunosuppressed patients.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Rituximab: heightened infection susceptibility. - Inactivated vaccines: may have reduced immunogenicity, monitor response.